Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementImpairment of autophagy ...

Spear Bio Inc., a biotechnology company pioneering next-generation ultra-sensitive immunoassays, today announced that its pTau 217 blood test has been granted Breakthrough Device Designation by the U.

An international commission made the case for focusing on body fat quantity and the illnesses people experience.

The Alzheimer's Accountability and Investment Act (Public Law 118-93), enacted on October 1, 2024, mandates that the National ...

Intra-Cellular’s clinical-stage pipeline is promising, with pipeline agents under development for a wide range of neurological indications.

In a new study published in The BMJ, we and our colleagues Vishal Patel and Michael Liu, also at Harvard, set out to study rates of Alzheimer’s deaths among taxi drivers and ambulance drivers, who ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according ...

By 2060, new dementia cases per year could double to one million because of the growing population of older Americans, a ...

ProMIS Neurosciences Inc. (Nasdaq: PMN) (ProMIS), a clinical-stage biotechnology company focused on the generation and ...

(OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced its ...

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b ...

WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology ...